Lemsip

Lemsip is a British over-the-counter medicine brand focused on relief of common cold and flu symptoms. Its best-known product is a lemon-flavoured hot drink sachet prepared with hot water. Traditional formulations combine paracetamol, an analgesic and antipyretic used to reduce pain and fever, with phenylephrine hydrochloride, a decongestant intended to relieve nasal congestion. Depending on the formulation, Lemsip products are marketed for symptoms including headache, fever, sore throat, blocked nose, and muscular aches and pains. The product was introduced in the United Kingdom in 1969 under the name LEM-SIP. During the 1970s, the brand was renamed Lemsip and adopted packaging featuring a distinctive sword-in-a-glass device. This visual identity helped associate the brand with a hot medicinal drink rather than a conventional tablet-based medicine. The hot-drink format remains central to Lemsip's identity and differentiates it from many competing cold remedies sold primarily as tablets or capsules. Lemsip expanded substantially in the 1990s with the introduction of the Lemsip Max range. Launched in 1995, Lemsip Max extended the brand into additional hot-drink flavours, including lemon, blackcurrant, and Breathe Easy, while also adding capsule products such as Lemsip Max Cold & Flu Capsules. The Max products were positioned around the maximum permitted levels of active ingredients for general-sale medicines in the United Kingdom, subject to the formulation and applicable regulatory requirements. Further product development broadened the range beyond simple paracetamol-and-decongestant combinations. In 2007, Lemsip introduced Max All In One hot drinks in flavours including lemon, wild berry, hot orange, and Breathe Easy. In 2008, a liquid version was added. These products included guaifenesin, an expectorant intended to help loosen chest mucus, alongside paracetamol and phenylephrine. The range subsequently came to include hot-drink sachets, capsules, tablets, and liquid preparations. Lemsip is part of Reckitt's consumer-health portfolio. Manufacturing associated with the brand has been reported at Reckitt facilities in Hull and Nottingham. The brand's principal market is the United Kingdom, where it has been a prominent branded over-the-counter cold-remedy product. A 2016 industry ranking cited Lemsip as the fourth-largest branded over-the-counter medicine in Great Britain by sales, with reported sales of £63.9 million for that year. That figure is historical rather than a current valuation or revenue estimate. The brand's products carry the safety considerations applicable to their active ingredients. Consumers can risk a paracetamol overdose if they use Lemsip together with another medicine containing paracetamol. Excessive paracetamol intake can cause severe organ damage. Formulations containing phenylephrine may also be unsuitable for some people because of contraindications, interactions, and possible adverse effects. In 2015, research and professional criticism questioned whether oral phenylephrine was effective as a decongestant, prompting some pharmacists to call for restrictions or removal of the ingredient. These concerns relate to formulation efficacy and medicine safety rather than to a proven defect in the Lemsip brand as a whole.

Lemsip originated in the United Kingdom as a hot-drink cold remedy. The product was first introduced in 1969 under the name LEM-SIP. Its format was distinctive for the period: rather than being presented only as a conventional tablet or capsule, it was dissolved in hot water and consumed as a lemon-flavoured medicinal drink. This preparation format became central to the brand's identity and positioned it as a comforting, convenient response to cold and flu symptoms. During the 1970s, the product was renamed Lemsip. The rebranded packaging included a sword-in-a-glass logo, a visual device that became associated with the product and reinforced its hot-drink presentation. Over time, Lemsip developed from a single core drink into a broader family of over-the-counter remedies. The brand remained focused on common cold and flu symptoms, including pain, fever, sore throat, and nasal congestion, while its formulations and delivery formats expanded. A significant stage in this development came in 1995 with the launch of Lemsip Max. The new range included hot drinks in lemon, blackcurrant, and Breathe Easy variants, and introduced capsule products such as Lemsip Max Cold & Flu Capsules. The Max name signalled a more comprehensive or high-strength positioning within the United Kingdom's general-sale medicine market. The range was described as containing the maximum permitted levels of active ingredients for general-sale listing, depending on the product formulation. In 2007, Lemsip extended the Max platform with Max All In One hot drinks. These were offered in flavours including lemon, wild berry, hot orange, and Breathe Easy. Unlike the original formulation, which principally combined an analgesic with a decongestant, Max All In One products were designed to address a wider set of cold symptoms. The following year, in 2008, the company added a liquid version. The cited formulation included guaifenesin for chesty cough symptoms, alongside paracetamol for pain and fever and phenylephrine hydrochloride for nasal congestion. The product portfolio eventually included capsules, tablets, liquids, and hot-drink sachets. This gave the brand several routes to market and allowed it to serve consumers seeking either the traditional warm drink format or a more conventional solid or liquid medicine. Lemsip has operated as part of Reckitt's consumer-health business, with manufacturing associated with Reckitt sites in Hull and Nottingham. The brand has also faced questions about the scientific basis for one of its recurring ingredients. In 2015, evidence and professional commentary challenged the effectiveness of oral phenylephrine as a decongestant. Because phenylephrine is used in Lemsip formulations alongside paracetamol, the debate had direct relevance to some products in the range. Some pharmacists called for the ingredient to be banned or otherwise restricted. Separately, product information has highlighted the risk of taking Lemsip with other paracetamol-containing medicines, since cumulative dosing can result in serious harm. By 2016, Lemsip was reported as the fourth-largest branded over-the-counter medicine in Great Britain by sales, with cited sales of £63.9 million. The figure illustrates the brand's historical importance in the UK market but should not be treated as a current financial measure. Lemsip remains a recognizable Reckitt cold-and-flu brand, centered on its established hot-drink heritage while maintaining a wider portfolio of cold-remedy formats.

• 2016

  Reported as fourth-largest branded OTC medicine in Great Britain

  [1]Lemsipen.wikipedia.org

  A cited market ranking placed Lemsip fourth among branded over-the-counter medicines in Great Britain, with reported sales of £63.9 million.

• 2008

  Max All In One liquid introduced

  [1]Lemsipen.wikipedia.org

  A liquid preparation was added to the Max All In One range, with guaifenesin included for chesty cough symptoms.

• 2007

  Max All In One hot drinks launched

  [1]Lemsipen.wikipedia.org

  Lemsip introduced a multi-symptom hot-drink line in multiple flavours.

• 1995

  Lemsip Max launched

  [1]Lemsipen.wikipedia.org

  The Max range added new hot-drink flavours and capsule products, broadening the brand beyond its original lemon drink.

• 1970

  Brand renamed Lemsip

  [1]Lemsipen.wikipedia.org

  During the 1970s, the product adopted the Lemsip name and packaging featuring a sword-in-a-glass logo.

• 1969

  Original LEM-SIP product introduced

  [1]Lemsipen.wikipedia.org

  The first version of the British hot-drink cold remedy was introduced under the name LEM-SIP.

A familiar UK cold-and-flu relief brand built around convenient hot-drink preparations and multi-symptom over-the-counter formulations.

• Cold and flu hot drink · 1969

  Lemsip Lemon Hot Drink

  The original and best-known Lemsip format is a lemon-flavoured hot drink prepared by dissolving a sachet in hot water. The cited formulation contains 650 mg of paracetamol and 10 mg of phenylephrine hydrochloride. It is intended to provide relief from symptoms such as headache, fever, blocked nose, body aches and pains, and sore throat.

• Cold and flu remedies · 1995

  Lemsip Max

  Introduced in 1995, Lemsip Max expanded the brand's original hot-drink proposition with lemon, blackcurrant, and Breathe Easy variants. The platform also included capsule products. Max products were positioned around the maximum permitted active-ingredient levels for general-sale medicines in the United Kingdom, subject to the individual formulation.

• Cold and flu capsules · 1995

  Lemsip Max Cold & Flu Capsules

  The capsule format extended Lemsip Max into a conventional solid-dose medicine. It was developed for consumers seeking the brand's multi-symptom cold-and-flu proposition without using a hot drink. The cited source identifies the product as part of the capsule range but does not provide a complete current formulation or product specification.

• Multi-symptom cold and flu hot drink · 2007

  Lemsip Max All In One Hot Drinks

  Launched in 2007, Max All In One hot drinks broadened the symptom coverage of the Lemsip Max platform. The cited variants included lemon, wild berry, hot orange, and Breathe Easy. The range used paracetamol and phenylephrine and was designed to address several cold symptoms in one preparation.

• Multi-symptom liquid cold remedy · 2008

  Lemsip Max All In One Liquid

  Added in 2008, the liquid version of Max All In One included guaifenesin for chesty cough symptoms in addition to paracetamol and phenylephrine hydrochloride. The cited formulation contains 1,000 mg of paracetamol, 200 mg of guaifenesin, and approximately 12.2 mg of phenylephrine hydrochloride, although the exact phenylephrine amount varies slightly by formulation.

• 2015

  Response to questions about phenylephrine effectivenessOther

  Background

  Research and professional commentary questioned whether oral phenylephrine provided meaningful decongestant benefits.

  Action taken

  Some pharmacists called for phenylephrine to be banned or restricted; the available source does not document a specific Lemsip product withdrawal or reformulation.

  Aftermath

  The issue created a continuing regulatory and efficacy debate relevant to Lemsip formulations containing phenylephrine.

  Source

• 2007

  Expansion into Max All In One remediesProduct launch

  Background

  Lemsip sought to provide a wider multi-symptom proposition within its established hot-drink format.

  Action taken

  Max All In One hot drinks were launched in several flavours.

  Aftermath

  The following year, the platform was extended with a liquid formulation containing guaifenesin for chesty cough symptoms.

  Source

• 1995

  Creation of the Lemsip Max platformProduct launch

  Background

  The established Lemsip hot-drink brand was expanded to cover more flavours and solid-dose products.

  Action taken

  The company launched Lemsip Max hot drinks and added capsule products, including Lemsip Max Cold & Flu Capsules.

  Aftermath

  Lemsip developed from a single signature drink into a broader cold-and-flu remedy portfolio.

  Source

• 2016

  Lemsip ranked among Britain's leading branded over-the-counter medicines[1]Lemsipen.wikipedia.org

  Other

  Lemsip was reported as the fourth-biggest-selling branded over-the-counter medication in Great Britain, with cited sales of £63.9 million for the year.

• 2015

  Questions raised over oral phenylephrine effectiveness[1]Lemsipen.wikipedia.org

  Regulation · Other

  Research and professional criticism questioned the effectiveness of phenylephrine as an oral decongestant, an ingredient used in major Lemsip formulations. Some pharmacists subsequently called for the ingredient to be restricted or banned.

• 2008

  Liquid formulation added to Max All In One[1]Lemsipen.wikipedia.org

  Product launch · Product generation

  The Max All In One line was extended with a liquid product containing guaifenesin as well as paracetamol and phenylephrine.

• 2007

  Lemsip Max All In One hot drinks launched[1]Lemsipen.wikipedia.org

  Product launch · Product generation

  Lemsip introduced multi-symptom Max All In One hot drinks in several flavours, combining pain and fever relief with decongestant and cough-related claims.

• 1995

  Lemsip Max range introduced[1]Lemsipen.wikipedia.org

  Product launch · Product generation

  Reckitt's Lemsip brand expanded with the Lemsip Max line, adding new hot-drink flavours and capsule products to the established cold-remedy range.

1. 1Lemsipen.wikipedia.org